ALPK3

ALPK3 Full Name

alpha-kinase 3

ALPK3 Introduction

ALPK3 (alpha-kinase 3) is a member of the alpha-kinase family, a distinct group of protein kinases characterized by their ability to phosphorylate substrates within alpha-helical structures rather than flexible loops or turns. Unlike the related family member ALPK2, which is broadly expressed in cardiac and other tissues, ALPK3 exhibits a highly restricted expression pattern, with highest levels detected in the heart and skeletal muscle. The gene encodes a large multidomain protein that plays essential roles in cardiomyocyte differentiation, sarcomere assembly, and cardiac development. ALPK3 is also known as MAK (muscle alpha-kinase) due to its predominant expression in striated muscle tissues. Mutations in ALPK3 have been identified as causes of pediatric cardiomyopathy, particularly hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), often presenting with early-onset and severe disease. ALPK3 has also been implicated in the regulation of myogenesis and muscle regeneration, positioning it as a critical regulator of muscle development and disease.

Figure 1. Schematic structure of ALPK3.

Regulation, Disease Mechanisms, and Therapeutic Implications
The expression and activity of ALPK3 are tightly regulated during cardiac development and in response to pathological stress. ALPK3 expression is highest during embryonic and neonatal stages, when active sarcomere assembly occurs, and decreases after birth but remains detectable in the adult heart. In response to cardiac stress including pressure overload, myocardial infarction, and heart failure, ALPK3 expression is upregulated, suggesting a compensatory or protective role. Transcriptional regulation of ALPK3 is mediated by GATA4, NKX2-5, MEF2C, and SRF, transcription factors that are master regulators of cardiac development and hypertrophy. Post-translationally, ALPK3 is regulated by phosphorylation and by interaction with its substrates. Mechanistically, loss of ALPK3 leads to reduced MYBPC3 phosphorylation, resulting in increased cross-bridge cycling, energy inefficiency, and contractile dysfunction. ALPK3 deficiency also disrupts the M-band structure, causing sarcomeric instability and myocyte death. Therapeutically, ALPK3 has been proposed as a target for treating heart failure. Enhancing ALPK3 activity or restoring MYBPC3 phosphorylation could improve cardiac contractility in patients with heart failure with reduced ejection fraction (HFrEF). Preclinical studies suggest that gene therapy with AAV9-mediated ALPK3 delivery improves cardiac function in mouse models of cardiomyopathy. Conversely, inhibitors of ALPK3 might be beneficial in certain contexts, such as in patients with hypercontractile HCM, where reducing ALPK3 activity could ameliorate excessive contractility. Additionally, ALPK3 mutation status may guide clinical management, with affected individuals requiring early surveillance, timely transplantation evaluation, and genetic counseling for family members.

Clinical Significance: Pediatric Cardiomyopathy and Heart Failure
ALPK3 has emerged as an important disease gene in pediatric cardiomyopathy, a leading cause of heart failure and sudden cardiac death in children and young adults. Biallelic loss-of-function mutations (homozygous or compound heterozygous) in ALPK3 cause a severe, early-onset form of hypertrophic cardiomyopathy (HCM) with onset often in infancy or early childhood. Patients present with marked left ventricular hypertrophy, systolic dysfunction, myocardial disarray, interstitial fibrosis, and elevated serum troponin levels. Many affected individuals progress to end-stage heart failure requiring cardiac transplantation within the first decade of life. Additional features may include congenital heart defects such as ventricular septal defect (VSD) and patent ductus arteriosus (PDA), as well as skeletal muscle involvement including hypotonia and elevated creatine kinase. Heterozygous carriers of ALPK3 mutations (single allele) are generally asymptomatic but may have mild cardiac abnormalities detectable by echocardiography or cardiac MRI, and they may be at slightly increased risk for adult-onset cardiomyopathy. Over 30 distinct ALPK3 mutations have been reported, including nonsense, frameshift, splice-site, and large deletion mutations, all consistent with loss-of-function mechanisms. Missense mutations in the alpha-kinase domain that disrupt catalytic activity have also been identified. Importantly, ALPK3-associated cardiomyopathy shows phenotypic overlap with other sarcomeric gene mutations but exhibits distinct features including early onset, rapid progression, and frequent need for transplantation. Genetic testing for ALPK3 is recommended in cases of pediatric HCM or DCM, particularly when no mutation is found in conventional sarcomere genes such as MYH7, MYBPC3, and TNNT2.

Alternate Names for ALPK3

ALPK3; alpha-kinase 3; alpha-protein kinase 3; KIAA1330; MAK; Midori; muscle alpha kinase; myocyte induction differentiation originator; muscle alpha-kinase; muscle alpha-protein kinase; MIDORI; FLJ12881; FLJ21176;